Compare Incyte Corporation (INCY) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Wells Fargo & Co — how do they compare? Incyte Corporation trades at $113.19 (market cap $22.85B), while Wells Fargo & Co trades at $83.27 (market cap $248.06B). The key difference: Wells Fargo & Co is far larger — about 10.9× Incyte Corporation's market cap, and Wells Fargo & Co pays a 2.44% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Wells Fargo & Co for 87 Days on average.
| INCY | WFC | |
|---|---|---|
Market Cap | $22.85B | $248.06B |
Volume | 1,927,029 | 16,615,741 |
Sector | Health | Financials |
52-Week High | $129.93 | $96.40 |
52-Week Low | $83.80 | $73.42 |
Typical Hold Time | 33 Days | 87 Days |
Enterprise Value | $18.35B | $503.91B |
Dividend Yield | — | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with 2025 revenue of $5.14B, net income of $1.29B, and impressive profitability margins (gross margin 92.62%, net margin 27.71%). Recent FDA approval for Atebrioz and pipeline expansion signal growth beyond JAKAFI. Valuation appears reasonable with P/E of 14.36 and P/S of 3.98.
Outlook remains positive with analyst consensus target of $132.43 (16.7% upside) and 52% buy ratings. Key opportunities include pipeline diversification and $4B sales target, while risks involve JAKAFI patent expiration post-2029 and competitive pressures. Strong cash flow generation ($1.41B operating CF) supports continued R&D investment.
Wells Fargo (WFC) trades at $83.16, up 3.61% today, showing resilience amid a bearish technical signal. The stock benefits from strong profitability with a 25.97% net margin and a modest P/E of 11.92, indicating potential undervaluation relative to earnings. Recent positive developments include a credit rating upgrade to 'A-' by S&P (Zacks Investment Research, 2026-10-01) and a renewed mortgage servicing agreement with Intercontinental Exchange (Business Wire, 2026-09-29).
The outlook is cautiously optimistic, supported by analyst consensus targets near $99.13 and improving net interest income prospects from Fed rate hikes. Key risks include volatile cash flows, with 2025 operating cash flow negative $19.0B, and execution challenges amid leadership transitions like the chief risk officer's retirement (Reuters, 2026-09-23).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
